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Gene Expression Profiles and Clinical Parameters for Survival Prediction in   
Stage II and III Colorectal Cancer Patients 
 
 
Mubeena Begum 
 
 
ABSTRACT 
 
Prediction of outcome in colorectal cancer (CRC) is currently based on the TNM staging 
classification; however, histopathological classification alone is insufficient for accurately 
predicting survival in stage II and III patients.  Studies indicate that microarray gene 
expression profiles can predict survival in CRC.  We hypothesize that tumor gene expression 
in combination with clinical parameters, is a better predictor of outcome in stage II and III 
colorectal cancers than the TNM stage classification alone. 
Clinical records and follow-up data were retrospectively reviewed for 58 Stage II and 
Stage III patients with primary colorectal cancer, who did not receive any neoadjuvant 
therapy preoperatively and whose samples had been previously analyzed for gene expression 
profiles using the Affymetrix U 133a Gene chip.  For molecular classification of patients as 
being at high or low risk for poor survival, samples were divided into two clusters by 
hierarchical cluster analysis of genes selected by SAM.  Univariate and multivariate analyses 
 
 
 
vii
using Cox proportional hazard models were done to identify significant prognostic factors  
The 3-year and 5-year survival estimates were 72.41% (SE=5.8%) and 55.17% 
(SE=6.7%), respectively, for all 58 patients.  Univariate analysis showed that advanced stage, 
older age, high-risk molecular classification, positive lymph nodes were the statistically 
significant prognostic factors of poor survival (p<0.05), while gender, preoperative CEA 
level, and family history of CRC in first degree relatives were not statistically significant.  In 
multivariate analysis molecular classification, age and body mass index were independent 
significant prognostic factors.  In Cox proportional hazard model, the estimated hazard ratios 
for Stage III vs II was 2.45 (95%CI: 0.85-7.04), for high vs low molecular risk was 3.83 
(95%CI: 1.22-12.06) and old vs young age was 3.72 (95%CI: 1.2-11.49).  Model containing 
clinical stage in conjunction with molecular risk, body mass index, and age was a stronger 
indicator of clinical outcome (p= 0.0056) than model with clinical stage alone.  
Gene expression profiles predict survival independent of clinical parameters, and the 
addition of gene expression profiles to stage is more predictive of survival than stage alone.  
Further analysis needs to be done to validate the molecular classification on an independent 
dataset. 
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CHAPTER ONE 
 
INTRODUCTION 
 
1.1 Background 
Colorectal cancer (CRC), cancer of colon and rectum, the third most common cancer 
worldwide and the second leading cause of cancer-related mortality in the US [1,2].  It is the 
second most site-specific cancer affecting both men and women (lung cancer is first, 
affecting both men and women, breast is the leader in women and prostate in men) [2].  The 
lifetime probability of developing colon cancer in men is 1 in 17 and in women it is 1 in 18 
[2].  A study conducted by Parkin, DM et al, 1999 [34] discusses that approximately, 6% of 
the American population will eventually develop invasive CRC and over 6 million 
Americans who are alive today will die of the disease. 75% of patients with CRC have 
sporadic disease, with no evidence of having inherited the disorder and 25% have a family 
history of CRC suggesting a genetic contribution. 
Majority of the colorectal cancers arise due to malignant transformation of an 
adenomatous polyp.  The malignant tumor arises from colonic epithelial cells that line the 
mucosa.  Transition from normal epithelium to adenoma and to carcinoma is due to acquired 
molecular events [1], that is, 85% of CRC are due to events which lead to chromosomal 
instability (CIN) and 15% are due to microsatellite instability (MSI).  These events alter 
chromosomes 5q (APC), 18q (DCC) and 17p (TP53) involved in DNA repair.  
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1.2 Colon and Rectum: Structure and function 
Colon refers to the upper six feet of the large intestine and rectum to the last five to six 
inches.  Together colon and rectum make up the large intestine.  The colon is made of four 
sections: ascending colon, transverse colon, descending colon and the sigmoid colon.  Cancer 
can develop in any of the four sections of the colon and in the rectum.  The distributions of 
colorectal cancer in the large intestine are: ascending colon and cecum-25%, transverse 
colon-15%, descending colon-5%, sigmoid colon-25%, rectum-25% and rectosigmoid 
junction-10% [43]. 
 Tumors on the right side of the colon near the cecum usually grow large enough to be 
painful and cause bleeding. As a result they commonly present with anemia from chronic 
blood loss.  Polyps commonly appear on the left side of the colon.  Cancer on the left colon 
usually grows around the colon wall and encircles it.  Common symptoms of a tumor on the 
left side include constipation and change in bowel habits.  Cancer can grow inward toward 
the hollow part of the colon or rectum, and /or outward through the wall of the colon or 
rectum.  In untreated cases the cancerous cells break away from the primary site and spread 
to distant organs through bloodstream or lymphatic system.  This process is called 
metastases. 95% of CRC are carcinomas, and 95% of these are adenocarcinomas. 
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1.3 Classification of Disease:  
The currently used staging system for CRC is UICC-AJCC TNM staging system.  The AJCC 
TNM staging system is considered to be more useful for clinical decision-making, due to its 
precise stratification.  It consists of three independent prognostic variables: the depth of 
tumor invasion into the bowel wall (T), the presence or absence of lymph node involvement 
(N), and the presence or absence of distant metastases (M) [21, 53]. The pathologic staging is 
assigned after the resection of the primary tumor, removal and examination of regional 
lymph nodes and analysis of the surgical specimen.  The AJCC/ UICC and Dukes’ 
classification system is shown in table 1.  The survival rates for the different staging systems 
are summarized in table 2. 
 
 
 
 
 
 
 
 
 
 
 
Fig1.  Anatomic Division and Tumor Penetration (AJCC 6th Edition System) 
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Table1. AJCC/UICC Staging Sytem for Colon and Rectal Cancer 
 
AJCC/UICC Description of AJCC Staging System Dukes’ MAC 
Stage 0 and Tis Carcinoma in situ: intraepithelial or invasion of the 
lamina propria. 
 
  
 
Stage I 
(T1 N0 M0) 
Tumor invades through the submucosa.  No metastases 
to regional nodes or distant metastases. 
 
Dukes’ A A 
Stage I 
(T2 N0 M0) 
Tumor invades into the muscularis propria.  No 
metastases to regional nodes or distant metastases. 
 
Dukes’ A B1 
Stage IIA 
(T3 N0 M0) 
Tumor invades through the muscularis propria into the 
subserosa, or into non-peritonealized pericolic or 
perirectal tissues, no metastases to regional nodes or 
distant metastases. 
 
Dukes’ B B2 
Stage IIB 
(T4 N0 M0) 
Tumor directly invades other organs or structures, 
and/or perforates visceral peritoneum, no metastases to 
regional nodes or distant metastases. 
 
Dukes’ B B3 
Stage IIIA 
(T1-2 N1 M0) 
Tumor invades submucosa or muscularis propria.  
Metastases in 1 to 3 regional lymph nodes.  No distant 
metastases. 
 
Dukes’ C C1 
Stage IIIB 
(T3-4 N1 M0) 
Tumor invades through the muscularis propria into the 
subserosa, or into non-peritonealized pericolic or 
perirectal tissues or tumor directly invades other organs 
or structures, and/or perforates visceral peritoneum.  
Metastases in 1 to 3 regional lymph nodes.  No distant 
metastases.  
Dukes’ C C2/C3 
Stage IIIC 
(Any T, N2, M0) 
Any extent of tumor invasion.  Metastasis in 4 or more 
regional.  No distant metastases. 
 
Dukes’ C C1/C2/
C3 
Stage IV Any extent of tumor invasion or number of metastases 
to regional nodes.  Distant metastases present. 
Dukes’ D D 
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1.4 Statement of Problem 
Prediction of outcome is an important aspect in cancer research.  In patients with colorectal 
cancer limited to the mucosa (TNM Stage I) and in patients with distant metastases (TNM 
Stage IV), the 5-year survival rates are 90-95% and <10%, respectively [2, 32].  In these 
patients histopathologic criteria (TNM staging) are good predictors of survival.  However, in 
patients with invasion of the colon wall or adjacent structures (stage II) and those who have 
regional nodal metastases (stage III), the probability of survival is about 70-85% and 40-80% 
respectively based on the TNM staging [32].  Moreover, patients with same tumor stages 
may show different prognosis indicating that conventional staging procedures may be unable 
to precisely predict cancer risk.  Thus, it is in stage II and III patients that a better predictor of 
survival is needed. As an alternative to clinical staging, recently developed microarray 
technology has permitted the development of multiorgan cancer classifier, identification of 
tumor subclass, discovery of progression markers, and prediction of disease outcome in many 
types of cancer.  Unlike clinicopathological staging, molecular staging is able to better 
predict the long-term outcome of an individual based on the gene expression profile of the 
tumor at diagnosis [11]. 
Preliminary studies indicate that microarray gene expression profiles have been most 
accurate to date in predicting the overall survival in CRC [11].  However, most research 
examining gene expression profile has not taken clinical parameters (stage, age, sex, grade, 
preoperative CEA levels) into consideration.  
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Table 2: 30 months and 60 months relative survival rate by AJCC sixth 
 Edition System [32].  
 
 
 
 
 
 
 
 
The 5-year survival rate refers to the percentage of people who live at least 5 years after their 
cancer is diagnosed.   
 
 
1.5 Study Purpose 
The purpose of the study was to investigate whether clinicopathological (TNM staging) 
based outcome (survival) prediction can be improved by combining microarray gene 
expression profiles together with other clinical predictors (age, sex, grade, preoperative CEA 
level).  
Stage ----------Æ Survival 
Stage+ GEP+ age + gender + body mass index (BMI)+ family history 
+ location of tumor+ grade+ preoperative CEA level     --------------- Æ Survival 
+ total resected lymph nodes  
 
 
 
Stage 30 months (%) 60 months % (5-year 
relative survival rate) 
Stage I 96.1 93.2 
Stage IIA 91.0 84.7 
Stage IIB 80.2 72.2 
Stage IIIA 91.4 83.4 
Stage IIIB 77.3 64.1 
Stage IIIC 59.1 44.3 
Stage IV 17.3 8.1 
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1.6 Research Question: 
1. What is the predictive value of traditional clinical predictors- age, sex, race, stage and 
grade in determining prognosis (survival) in Stage II and III CRC patients? 
2. What is the predictive value of gene expression profiles (GEP) by itself in this 
sample? 
3. What does the addition of GEP together with clinical parameters (age, sex, family 
history, BMI, grade, location of tumor, preoperative CEA levels) contribute to the 
usual clinical predictiveness of outcome (survival) in stage II and III colorectal 
cancer?   
 
1.7 Hypothesis 
Gene expression profiles (GEP) and clinicopathological factors (age, sex, BMI, family 
history, grade, preoperative CEA level) add to the predictive value of staging in predicting 
the postoperative outcome (survival) in stage II and III CRC.
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CHAPTER TWO 
 
REVIEW OF LITERATURE 
 
2.1 Descriptive Characteristics 
 
 Currently CRC constitutes 10% of new cancer cases in men and 11% new cancer 
cases in women.  Estimated new cases and deaths from CRC in the US in 2005 are 104,950 
new cases and 56,290 deaths [2].  SEER data for 1998-2002 show the overall incidence of 
CRC is higher in men (62.1/100,000) than in women (24.8/100,000), and this holds true for 
mortality rates, in men (46.2/100,000) and women (17.4/100,000).  The median age at 
diagnosis in the United States, during this period is 70 for men and 74 for women.   
 Incidence is higher among African American men and women (62.4%) compared to 
White men and women (52.5%), and so are the mortality rates in African Americans (20%) 
to Whites (27.9%). The risk of CRC increases after the age of 50-55 years and continues to 
rise exponentially with increasing age. Between 1998 and 2001, the incidence rate has 
declined by 2.9% and 5-year survival rate has increased by 7.3%, which could be due to 
advances in detection and screening and the increasing use of combination therapies [40].   
 Although the exact cause of CRC cancer is unknown, several factors play a crucial 
role in the development and prognosis of CRC survival, which can be classified as prognostic 
factors (tumor related, host related and environmental related factors) and risk factors. 
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 Definition of Prognostic Factor: In epidemiological literature prognostic factor 
refers to the probability of future event in patients who currently have a disease. It implies 
prediction of an event that will occur in the future. It can be considered in the context of 
probability of cure or prolongation of survival. Knowledge of prognostic factors helps us to 
understand the progress of the disease [19].  
 Definition of a Risk Factor: “A clearly defined occurrence or characteristic that has 
been associated with the increased rate of a subsequently occurring disease”. It is limited to 
those who don’t have a disease [19].  
 
2.2 Prognostic Factors 
 2.2.1 Tumor related prognostic factors 
♦ Pathological staging: Is the most important predictor of outcome in patients with 
newly diagnosed colorectal cancer [39, 52], which depends on the degree of 
penetration of tumor through the bowel wall, presence of or absence of nodal 
involvement and presence or absence of distant metastasis.  Majority of the CRC are 
adenocarcinomas. 
♦ Histological grade:  Tumor prognosis correlates with histological grade: poor 
differentiation has a worse prognosis than a high degree of differentiation [39, 45].  
Large studies have shown that histological grade correlates with survival and 
recurrence, with low-grade tumors having better survival [21]. Venous, lymphatic and 
perineural invasion have also shown to decrease survival and increase the risk of local 
recurrence [21, 52]. 
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♦ Surgical margins and radial margins: The presence of positive surgical or radial 
margin is a poor prognostic factor, with local failure rate in all stages increasing from 
3%-85% [37]. 
♦ Molecular markers: The use of molecular markers that have prognostic significance 
aids in identifying high-risk patients who can benefit from adjuvant chemotherapy 
and avoiding those who have low risk from the toxicities of adjuvant chemotherapy.  
Presence of microsatellite instability has shown to improve prognosis in sporadic 
colorectal cancers [20, 22].  Three studies have independently shown unfavorable 
prognosis of patients with the loss of 18q in stage II and III CRC [24, 33, 41].  
♦ Carcinoembryonic antigen (CEA): CEA levels are used to monitor the course of 
colorectal cancer.  Elevated pre-operative levels of CEA at diagnosis, has shown to be 
an independent prognostic factor for survival and recurrence in CRC patients [21]. 
♦ Lymph nodes examined: AJCC and NCI recommend that at least 12 lymph nodes 
should be examined in patients with colorectal cancer to confirm the absence of nodal 
involvement by tumor [9].  It is a reflection of the aggressiveness of lymphovascular 
mesenteric dissection during surgery and pathological identification of nodes in the 
specimen.  Retrospective studies have demonstrated that the number of LN examined 
in CR surgery may be associated with patient’s outcome [47].  A study by Berger. A. 
C et al., 2005, have demonstrated that lymph node resection is a statistically 
important prognostic factor for determining overall survival and disease free survival. 
 
 2.2.2 Patient-related prognostic factors: 
♦ Genetic Syndromes: Patients with Hereditary Nonpolyposis colorectal cancer 
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(HNPCC- is a familial syndrome in which individuals develop CRC before 50 years 
of age), chronic ulcerative colitis (UC- inflammatory condition of the large intestine) 
and Familial adenomatous polyposis (FAP- an autosomal dominant condition 
characterized by multiple polyps with high potential to progress to cancer) are at 
increased risk of colorectal cancer [51]. 
Hereditary Nonpolyposis Colorectal Cancer (HNPCC):  Also called Lynch 
Syndrome.  It is an autosomal dominant condition caused by mutation in the DNA 
mismatch repair genes (hMSH2, hMLH1).  HNPCC accounts for about 3-5% of all 
CRC [2].  They have increased risk of developing adenomas at an early age, the 
average age of CRC diagnosis in HNPCC syndrome patients is around 44 years [2].  
They also have an increased risk of developing other cancers such as endometrial, 
ovarian, small intestine, pancreatic, renal pelvis and brain tumors. 
Familial Adenomatous Polyposis (FAP): is an autosomal dominant condition with a 
prevalence of 1/8,000 [2].  FAP is due to mutation in the APC gene on chromosome 
5q21.  The disease is characterized by hundreds of polyps in the colon and rectum, 
which develop after the first decade of life.  By the age of 20 and 30 the probability of 
developing colonic adenoma increases by 75% and 90%, respectively [2].   
♦ Familial Colon Cancer: A positive family history is an important risk factor 
developing CRC.  A two to three-fold increase in risk is seen if an individual has a 
first degree relative with CRC and the risk increases if more relatives are affected 
[40].  Family history of CRC is seen in 10-15 % of persons with CRC.  This increases 
the person’s risk to develop CRC by 2-6 fold.  With a family history, the risk of CRC 
increases earlier in life (less than 45 years) than later. 
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♦ Age:  3 % of the CRC arise before age of 30 years, and 11% have predisposing 
conditions such as FAP and UC.  The risk of CRC increases with age and it is most 
common in men and women above 55 years.  Studies have reported poor prognosis in 
CRC patients who are less than 40 years [1].  Tumors with microsatellite instability 
(MSI) have better prognosis irrespective of age [2]. 
♦ Racial difference: Racial differences in the overall survival were observed in few 
studies although some studies have shown that co-morbid conditions play a role in the 
survival outcome in different patient population. Jews of European decent have a 
higher rate of CRC due to genetic mutation. 
♦ Weight: Many studies have reported an increased risk of colorectal cancer with 
increasing body mass index [10]. Having excess fat in the waist are (intra-abdominal 
fat) increases the risk more than having the same amount of fat distributed in other 
areas (thighs, hips). Obesity placed men more than women at increased risk for colon 
cancer. This association in men is due to greater waist circumference in men and the 
protective effect of estrogen in women, which decreases CRC risk. A study by 
Giovanucci et al., 2001 [16] found a correlation between colon cancer and type-2 
diabetes. Obesity predisposes a premenopausal woman to the same risk as does for 
men in general [12]. 
♦ Geography: rates of colorectal cancer vary geographically. The disease is more 
common among industrialized nations –USA, Western Europe, Australia and 
uncommon in Asia, Africa and South America [48]. 
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Table: 3 Literature Review of Clinical and Pathological Factors Assessed by Cox Multivariate Analysis 
 
 
Author, year  Study Features  Factors Analyzed   Findings and Strengths/Weakness 
 
Bertucci, F et al. 2004  Prospective study Gender, age, site of tumor, grade, Significance of prognostic classification made by AJCC  
[5] Single institution, France tumor penetration, LN involvement, stage and the obtained gene set was compared.  
 Sample size: 50 samples vascular invasion, stage, surgery,  Classification based on AJCC stage was significant but  
 (26 patients) between less than that made by gene expression profiles.  
 1990-1998.  prognostic impact of gene set persisted when applied to  
 All tumor sections and patients without metastasis at diagnosis and patients  
 Medical records were reviewed without metastasis and LN involvement.  
 prior to analysis.  Strengths: Accuracy of prediction of “molecular 
 Unsupervised hierchical  metastatic signature’ was estimated by leave one 
 clustering was used to investigate  out procedure. DNA microarray was able to identify 
 relationship between samples  clinically relevant tumor subgrous based on the gene   
 and genes.  cluster.  
  Weakness: Multivariate analysis was not done to  
  determine significant clinical and pathological factors 
  affecting survival. 
       
 
Barrier, A. et al., 2005 Prospective study Gender, stage, grade and location. 70 gene predictor was built, 35 were overexpressed in  
[3] Sample size: 18patients Prognostic prediction was build   patients who developed a recurrence and 35 in patients 
 Stage II and II CRC patients based on microarray gene expression  who were disease free for 5 years.  
 Follow-up:  measure for stage II and II CRC  Strengths: Double cross validation was done by splitting  
 Every 3 years-1st postoperative patients. For each dataset a total  the data into testing and training set. The results of the  
 thereafter. of 150 prognosis  study suggest the ability to build a prognosis predictor  
 year and every 6 months  predictors were considered  and  for both stage II and III CRC, based on either T or NM  
 Performance was assessed  gene expression profiles. The accuracy of the 70-gene 
 using six-fold cross-validation. NM based predictor was greater than that of 30-gene  
 based predictor (83 vs 78%). 
 Weakness: The study did not analyze the effect of  
 Clinico pathological factor in association with gene 
 Expression profiles in predicting the survival. 
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Author, year  Study Features  Factors Analyzed  Findings and Strengths/Weakness 
 
 
 syndrome, cancer with IBD, Dukes’ stage, grade, microsatellite regulation and Dukes’ stage, LN status. VEGF  
 rectal cancers were excluded  status, resected nodes, postoperative overexpression correlated significantly with Dukes’ stage. 
 because their molecular feature,  complications, recurrence. Strengths: Study compared levels of p53, p27, VEGF 
 recurrence rate, and overall  molecular and structural markers- and MVC, which are involved in cycle regulation,  
 differs from sporadic colon  P53, P27, VEGF, microvessel count apoptosis, and tumor neoangiogenesis, for normal 
 cancers.  and colon cancer cells with clinopathological variables. 
 In conjuction with clinicopathological staging, molecular  
 Expression markers p27, p53, VEGF, provide a stronger 
 Indication of clinical outcome than with staging alone and help  
 better select therapeutic option in colorectal cancer patients. 
 
 
 
 
 
Murphy T K et al. 2000  Large prospective study Age, sex, smoking and alcohol. The study was done to examine the association between BMI and  
[31] Population based, 50 States history, dietary history, exercise,  colon cancer mortality in both men and women. The findings in  
 Sample size: 1,184,659 estrogen replacement therapy  the study were that BMI was an independent risk factor for colon 
 Follow –up: 12 years and asprin use. cancer death in both sexes and the relationship is stronger and  
 1616 final sample size BMI was categorized for age  more linear in men than in women. This could be due to central  
  followinginclusion and and gender. obesity causing  hyperinsulinemia and increased glycemic load 
 exclusion criteria causing tumor growth.  
 Alcohol intake significantly modified the association between  
 BMI and colon cancer mortality. 
 Strengths: Large prospective study, generalizeable to the  
 Population. 
 Weakness: lack of screening data, self reported measurements. 
 Did not look into other clinicopathological factors which affect 
 survival in CRC. 
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Author, year  Study Features  Factors Analyzed   Findings and Strengths/Weakness 
 
 
Ponz de Leon et al, 1992 Population based study Age, site of tumor, family history, Factors which were significant in univariate analysis  
[35] Sample size: 132  interval between diagnosis and  analysis were: age, pattern of growth and extent of  
 Follow-up: 5 years  surgery, interval between symptoms   fibrosis. However, the only significant factor related to  
 Post operatively and diagnosis, stage, pattern of  prognosis in multivariate analysis was stage. 
 Equal number of male growth, extent of fibrosis.  Staging being the factor significant in multivariate  
 and female patient’s analysis confirms the importance of stage in predicting  
 survival in CRC. 
 
 
 
 
Prall, F et al. 2004 [36] Retrospective study with review Clinical and immunohistochemical In Cox multivariate analysis growth pattern of tumor,  
 of clinical charts and medical tumor marker levels were estimated lymphohistiocytic response, lymphatic permeation, and  
 records. (p53, p27, p21 levels).  extramural venous were found to be significant when  
 Sample size: 184 tested against UICC stage. Mitotic index added to the  
 All stages of CRC prognostic information to TNM stage in multivariate  
 Follow-up history was obtained analysis.  
 for 5 years postoperatively. Weakness of study: Effect of other prognostic markers  
 in combination with tumor markers (p53, p27, p21) 
 was not done on CRC patients in predicting survival. 
 
 
 
 
Rene A. C. et al. 2004 Retrospective study Age, Gender, Karnofsky  Study determine better survival (5-year) rate  
[39] Sample size: 96 patients performance at admission,  for patients undergoing curative surgery (58.3%) than 
 From 1950 to 1990. site of tumor, type of surgery, palliative surgeries (0%).  
 Follow-up: 3 years preoperative albumin level, Multivariate analysis showed Karnofsky performance  
 All stages of CRC number of resected organs/ status was strongly related to the risk of postoperative  
 structure, hospital stay, grade, complications and postoperative deaths.  
 stage, lymph node status, Factors which were related to better prognosis for CRC, 
 lymphatic invasion, perineural were grade I and II,  non metastatic LN, absence of   
 invasion, tumor margins,  vascular, lymphatic, perineural invasion,  
 clinical presentation. Poor prognostic factors were lympn node status and  
 adjacent organ infiltration.  
 Strengths: A significant decrease of postoperative deaths 
 and complications from 1950 to 1990 could be due to 
 improvement in staging methods, pre and post operative and  
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Author, year  Study Features  Factors Analyzed   Findings and Strengths/Weakness 
 
  
 
Ratto, Carlo et al, 1998  Prospective study Gender, Age (</> 60 years) Factors significant and independently influencing 
[38] Sample size: 853  Location of primary outcome were gender, lymph node involvement,  
 Male and female patients  history of bowel obstruction history of metastasis and bowel obstruction. 
 With CRC of all stages  Tumor size, Stage, Grade,   Strengths:  Large sample size and good power, 
 Follow-up:  LN involvement, Metastasis,  including tumor markers similar results were 
 Every 3months-1st year Preoperative CEA, tumor ploidy observed in other studies too. 
 Every 6 months in 2nd-3rd year, and vascular invasion. Weakness: Did not look into molecular markers 
 once per year thereafter on survival prediction. 
 
 
  
 
Wang et al. 2004 [50] Retrospective study with review Clinicopathological information was  The study demonstrates the potential of DNA microarray based   
 of clinical charts. collected. The sample was divided into  gene expression pattern for the prediction of patient’s outcome  
 Sample size: 74 Dukes’ B patients 2 groups –testing and training set to select in colon cancer. This is likely to have an impact on the current  
 Follow-up history for 3 years gene markers using the training set and  clinical practice for the eligibility of adjuvant chemotherapy on  
 build a prognostic signature and validate  treatment of Dukes’ B colon cancer patients. The study  
 it on the testing set.  identified 23-gene signature that predicts recurrence in Dukes’ B 
 patients. The signature was validated in 36 independent patients. 
 The overall accuracy was 78%.  
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CHAPTER THREE 
 
METHODS 
 
3.1 IRB Approval 
 Prior to the initiation of the research, the study was approved by the Institutional 
Review Board (IRB) of the University of South Florida. 
 
3.2 Study Design and Study Population 
Retrospective cohort study with the review of clinical charts of 116 CRC patients; 
who underwent curative surgery from 1/5/1993 to 5/1/2002, at Moffitt Cancer Center and had 
a follow-up history up to the date of last contact or death.   
Initial study started with the selection of 400 frozen tumor specimens of patients with 
any of the four colorectal cancer tumor staging from Moffitt Cancer Center Tumor Bank 
(Tampa, Florida); such that all patients had postoperative follow-up for at least 36 months 
(because majority of patients who would die of CRC, will have done so by then) determined 
by Moffitt Cancer Registry.  The sample size was reduced to 116 as gene expression 
profiling using mRNA technique was done to only 116 samples of the 400 CRC tumor 
samples. 
Retrospective review of inpatient charts, including operative and pathologic reports of 
the 116 stages II and III CRC was done to obtain clinicopathological data.  Data was 
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collected on patient’s demographics, clinical, pathological and survival data.  A copy of the 
data entry form is provided in Appendix 1.  Once the data was collected, in order to maintain 
the patient confidentiality each patient was given a unique identification number generated 
by SAS Randomisation.  These data were entered on a standardized data entry form and 
entered into a database.  Based on the exclusion criteria the final sample size was reduced to 
58 patients consisting of confirmed stage II or stage III primary colorectal cancer only.  
 3.2.1 Inclusion Criteria: 
Confirmed Stage II and Stage III primary colorectal cancer patients, who did not receive any 
neo-adjuvant therapy preoperatively and, who had a follow-up of at least 36 months and also 
had gene expression profiling done using the mRNA technique. 
 3.2.2 Exclusion criteria:  
As the study addressed only primary colorectal cancer 41 samples were excluded from the 
116, who were Stage I or Stage IV colorectal cancer patients and also those for whom the 
cancer site were not colorectal such as (abdominal wall, periaortic lymph nodes, mesenteric 
lymph node, lung, liver, bladder, retroperitoneal lymph nodes, kidney, small intestine) after 
reviewing the histopthological reports.  Five patients had multiple primaries at the time of 
surgery and were assessed by the histological grade to determine the earliest primary and 
only the earliest primary was considered in the sample size and the others were excluded.  
Nine patients who received preoperative neoadjuvant therapy such as radiated rectal cancers 
were dropped from the study, as preoperative neoadjuvant therapy would affect gene 
expression profiles, hence cannot be used as predictor.  Histopathological information could 
not be reconfirmed for three patients and were excluded from the sample size.  Clinical and 
histoathological characteristics of patients and their tumors are summarized in tables 6 and 7.   
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3.3 Gene expression profiles (GEP) and Molecular classification:   
 The Gastrointestinal Tumor Program, Bioinformatics and Biostatistics Core of 
Moffitt Cancer Center and Research Institute performed the GEP of the 116 colorectal cancer 
specimens. 
 The microarray data was analyzed using Significance Analysis of Microarrays 
program (SAM) with censored survival data [11]. SAM identified genes most correlated with 
survival time (3-year survival) and used permutation analysis to estimate the False Discovery 
Rate (FDR). The first analysis was done for stage II and III CRC patients only. The data was 
preprocessed using Robust microarray (RMA) and the censored survival time was calculated 
for each sample. In this work, censoring occurred at time of last follow-up or for death in 
which there was no evidence of disease. SAM was used to calculate genes that correlated to 
survival time.  A threshold yielding a 10% median FDR was selected, which resulted in 53 
overexpressed genes.  The analysis was repeated for cases of all stages (stage I, II, III, IV). 
The data was again preprocessed using RMA and survival time was calculated. SAM was 
again used to select genes. A median FDR of 2.5% (the minimum FDR possible) was 
selected, resulting in 30 genes.   
 The gene expression for all 30 genes was extracted and the data was clustered.  The 
Gene Cluster 3.0  program for clustering and Java Treeview for visualizing the heatmap was 
used.  The genes were median centered and normalized prior to clustering.  Hierarchical 
clustering with the un-centered correlation similarity metric and complete linkage was used.  
The resulting dendrogram can be seen below. This resulted in two main groupings (Clusters) 
of the sample (columns) in the data, which were chosen as the “prognostic” groups for this 
work. These groups were listed as Cluster 1(Low risk) and Cluster 2 (High risk) based on 30-
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gene cluster.  Cluster Analysis of 30 SAM selected genes were performed. Red color 
represents over expressed genes relative to green, underexpressed genes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2. Dendrogram 
 
3.4 Censoring 
Patients were considered for censoring when incomplete information was available about 
their survival time that is if they were lost to follow-up, alive with no evidence of CRC at the 
date of last contact or who died but not due to CRC.  Patients who did not die of CRC were 
considered censored and patients who died of colorectal cancer at the end of the study were 
considered as having experienced the outcome of interest (death) and were not censored. 
3.5 Statistical Analysis 
Univariate analysis and Kaplan-Meier procedure was done to find predictive value of each 
prognostic variable.  Multivariate analysis using stepwise selection procedure was done to 
determine the effect of GEP in the presence of other clinical predictors.  Final model 
selection was based on factors which met proportional hazard assumption and/or had 
biological or clinical significance.  
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CHAPTER FOUR 
 
DATA ANALYSIS 
 
4.1 Descriptive Analysis: 
A total of 58 patients matched the inclusion criteria for the study and all patients had 
undergone curative surgery for cancer.  Preliminary descriptive analyses were performed to 
characterize the sample.  Frequency and percentages for each variable were obtained 
accounting for the missing values.  Table 6 and 7 summarizes the clinical and pathological 
characteristics of patients and their tumors. 
Age at diagnosis was calculated as date of surgery minus the date of birth.  Mean, 
median and age range at diagnosis were determined.  Age at diagnosis was divided into 3 
groups: less than 50 years, 50-70 years and above 70 years.  To further determine the 
influence of advanced age on survival, age at diagnosis was divided into tertiles of upper 1/3 
rd age group and lower 2/3 rd age group.  
Body mass index was calculated based on the height and weight at the time of surgery 
of index primary colorectal cancer and divided into 4 groups: less than 18.5 (underweight), 
18.5-24.5 (normal), 25-29.9 (overweight) and above 30 (obese).  To further assess the effect 
increased BMI on overall survival, BMI was divided into 2 groups: ≤ 25 and >25.  
Location of primary cancer was merged into three groups: proximal colon (cecum, 
ascending colon, hepatic flexure and transverse colon), distal colon (splenic flexure, 
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descending colon and sigmoid colon) and rectum and rectosigmoid junction.   
 Tumor stage at the time of primary cancer was regrouped into two groups with Stage 
IIA and IIB grouped as stage II, and stage IIIA, IIIB and IIIC grouped as stage III, because 
there were very few patients in stage IIB and III A (table 6).  
Mean and range of Lymph nodes taken at the time of resection of primary tumor were 
determined and also grouped into ≤12 lymph nodes and greater than 12 lymph nodes.  
Survival differences for regional lymph node (LN) involvement were assessed for: 
No LN involvement, 1-3 group of LN’s, ≥ 4 group of LN.  Further analysis was done by 
collapsing the regional lymph node involvement into: lymph node positive group and lymph 
node negative group. 
Histological differentiation was categorized based on the grading: well-differentiated, 
moderately differentiated and poor differentiation.  Since, the number of patients in the well-
differentiated group were few, these patients were merged with patients with moderate 
differentiation to compare survival with poor differentiated tumors.  For preoperative CEA 
level was divided into < 5ng/ml and >5 ng/ml.  
Information on the vital status and cancer status at the date of last contact was 
obtained through the Moffitt cancer registry and summarized in table 5.   
 
4.2 Statistical Analysis  
Once the descriptive analysis was performed on the study population, the research 
questions were analyzed using SAS 9.0 software.  
Survival distribution were estimated using the Kaplan-Meier procedure to assess the 
influence of individual predictors (clinical parameters and GEP) on the overall survival of 
patients in the study, to determine which parameters met the proportional hazard assumption 
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and if there was significant difference between the strata for each parameter (predictor). 
Univariate analysis was done to determine statistically significant prognostic factors, the 
hazard ratios, confidence interval and p-values.  Log-rank test was used to compare survival 
estimates for each stratified variable.  Log-rank test was employed to evaluate the null 
hypothesis being tested that no overall survival difference exits between the strata for each 
variable.  Hypotheses were tested using p-values of 0.05 for statistical significance. 
Multivariable analysis using stepwise Cox regression analysis was used to determine 
independent significant prognostic variables.  The likelihood ratio test based on maximum 
partial likelihood estimates was used to eliminate confounding variables from the model.  
Variables were considered eligible for removal if the likelihood ratio test significance level 
was >0.05.  
The final model contained factors that met the proportional hazard assumption and had a 
biological or clinical significance in predicting colorectal cancer survival.  Survival rates 
were estimated by Cox proportional hazard model. Stepwise regression methods were used to 
build statistical model for the association of prognostic factors with overall survival.  Time 
dependent hazard ratios were estimated.  By observing HR, 95% CI for each factor, and the 
change in the log likelihood statistic, it was ascertained which variables should remain in the 
final model. 
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CHAPTER FIVE 
 
RESULTS 
 
5.1 Descriptive Analysis 
5.1.1 Demographic data  
Table 6 displays the demographic (clinical) characteristics of the 58 CRC subjects in 
the study.  
The median survival time for the study sample was 75.36 years and the 3-year and 5-
year overall survival estimates were 72.41% (SE=5.8%) and 55.17% (SE=6.7%), 
respectively (Fig 3).  
 
Fig 3 Kaplan Meier Curve for Overall Survival of the Study Population 
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Female patients had higher incidence rate of CRC (53%) than males (47%).  In the 
study sample, CRC was more commonly seen among Caucasians (81%), followed by African 
Americans (4%) and Hispanics (2%). BMI of majority of the patients (58%) was above 
normal (>25) at surgery. History of weight loss at the time of surgery was reported by 45% of 
CRC patients. Positive family history for CRC in first degree relative was present in only 8 
of the 58 patients. 
Based on age, 10% were in the <50 years age group, 38% were 50-70 years age group 
and 52 % were >70 years, at diagnosis. The median survival time for <50 years, 50-70 years 
and >70 years at surgery was 4.8 years, 5.12 years and 3 years, respectively.  Majority of the 
individuals diagnosed with CRC were of the between 70-79 years of age (35%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4 Age distribution of the study population 
 
At the end of 3 year follow-up 42 patients (72%) were alive and 16 patients were 
dead (28%). At the date of last contact 29 patients (50%) were alive with no evidence of 
cancer, 18 patients (31%) were dead with evidence of cancer, 4 patients (7%) died but with 
no evidence of cancer and cancer status could not be ascertained for 7 patients (12%). 
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Table 4 Survival Status at the end of 3-year follow-up 
Vital Status n % 
Alive 42 72 
Dead 16 28 
 
 
 
 
 
 
Table 5 Cancer Status at the Date of Last Contact 
 Cancer Status at Last Contact 
Vital Status at 
Last Contact 
No evidence of 
Cancer 
Evidence of 
Cancer 
Unknown 
Alive (n=31) 29 0 2 
Dead (n=27) 4 18 5 
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Table 6 Clinical Characteristics of Patients 
 
  Characteristics   
No. of 
Patients (%) 
  Total Sample Size (n)  58   
  Age at Diagnosis, years     
  Mean 67.17 years    
  Median  70.47 years    
  Age Range 26.97 - 92.41    
  ≤ 50 years  6 (10) 
  50-70 years  22 (38) 
  ≥ 70 years  30 (52) 
  Upper 1/3rd Age group (≥ 74.75 years)  19 (33) 
  Lower 2/3rd Age group (< 74.75 years)  39 (67) 
  Gender     
  Female  31 (53) 
  Male  27 (47) 
  Race     
  Caucasian  47 (81) 
  African American  4 (7) 
  Hispanic  2 (3) 
  Asian  1 (2) 
  Other/Unknown  4 (7) 
  Body Mass Index     
  <18.5 (underweight)  1 (2) 
  18.5-24.9 (normal)  18 (31) 
  25.9-29.9 (overweight)  21 (36) 
  ≥ 30 (obese)  13 (22) 
  Unknown  5 (9) 
  History of Smoking     
  Ever  25 (43) 
  Never  28 (48) 
  Unknown  5 (9) 
  Ever Female (n=31)  15 (48) 
  Ever Male (n=27)  10 (37) 
  Family History of Cancer     
  Present  34 (58) 
  Absent  12 (21) 
  Unknown  12 (21) 
  Family History of Colorectal Cancer     
  Present  8 (14) 
  Absent  38 (65) 
  Unknown   12 (21) 
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5.1.2 Histopathological Characteristics:  
Table 7 displays the histopathologic characteristics of the sample population as 
described below. 
The three most common site descriptions of CRC were sigmoid colon (27%), 
ascending colon (25%) and rectosigmoid junction (17%).  Based on the AJCC classification-
6th edition, in the study sample, 26% were stage IIA, 3% were stage IIB, 2% were stage IIIB, 
14% were stage IIIB and 13% were stage IIIC colorectal cancers. Stage IIA and IIB when 
combined together constituted 46% had Stage II CRC and stage IIIA, IIIB, IIIC when 
combined together constituted 56% of colorectal cancers in the study.  Of the patients 
observed, 47% had no regional lymph node involvement, 29% had 1-3 group of regional 
node positivity and 21% had more than 4 group of lymph node involvement.   
Moderate differentiation of the tumor (76%) was the most common histological grade 
in the sample population followed by poor differentiation (16%) and well-differentiated 
tumor (7%). Pretreatment CEA levels were unknown for 59% of the patients. 17% had 
preoperative CEA level more than 5 ng/ml and 24% had levels < 5ng/ml.  Based on the gene 
cluster analysis 47% were classified as low-risk group and 53% were of the high-risk 
group.Other histological features observed were vascular invasion (13 patients), lymphatic 
invasion (7 patients) and perineural invasion (3 patients). In addition to adenocarcinomatous 
histology, mucinous histology of tumor was observed in 5 patients.  Perineural, lymphatic 
and vascular invasion was seen in 3 patients, 7 patients and 13 patients, respectively.  
Resected margins were not clear of cancer after surgery with curative intent in 4 patients 
only. 
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  Table 7 Histopathological Characteristics of Patients 
  Characteristics No. of Patients (%)   
  Location of Primary     
  Proximal colon 21 (36)   
  Cecum & Ileocecal Valve 2    
  Acending colon 15    
  Hepatic flexure 0    
  Transverse colon 4    
  Distal Colon 20 (34)   
  Splenic flexure 0    
  Descending colon 4    
  Sigmoid Colon 16    
  Rectum and rectosigmoid junction 17 (29)   
  Rectosigmoid junction 10    
  Rectum 7    
  Stage     
  IIA (T3 N0 M0) 26 (45)   
  IIB (T4 N0 M0) 3 (5)   
  IIIA (T1-2 N1 M0) 2 (3)   
  IIIB (T3-4 N1 M0) 14 (24)   
  IIIC (Any T N2 M0) 13 (23)   
  Regional Lymph Node Metastasis     
  No Lymph node involvement (N0) 27 (47)   
  1-3 Lymph node involvement (N1) 17 (29)   
  ≥ 4 Lymph node involvement (N2) 12 (21)   
  Could not be assessed (Nx) 2 (3)   
  Total Lymph Nodes Resected     
  Mean Lymph nodes resected 13.63    
  Range of Lymph nodes examined 2 - 35    
  ≤ 12 28 (48)   
  >12  30 (52)   
  Grade/Differentiation     
  Well 4 (7)   
  Moderately 44 (76)   
  Poor 9 (16)   
  Unknown 1 (2)   
  Preoperative CEA* level     
  CEA ≥ 5.0 ng/ml 10 (17)   
  CEA < 5.0 ng/ml 14 (24)   
  Unknown 34 (59)   
  Molecular Classification     
  Low risk (Cluster 1) 27 (47)   
  High risk (Cluster 2) 31 (53)   
  Other Histological Features     
  Mucinous Histology 5    
  Signet Ring Histology 0    
  Perineural Invasion 3    
  Lymphatic Invasion 7    
  Vascular Invasion 13    
  Resected Margins Not Clear of Cancer 4    
  *  CEA: Carcinoembriyonic Antigen       
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5.2 Statistical Analysis 
The research questions are restated in this section to facilitate coherence and readability. 
The first two research questions are stated as follows: 
1. What is the predictive value of traditional clinical predictors- age, sex, race, stage and 
grade in determining prognosis (survival) in Stage II and III CRC patients? 
2. What is the predictive value of gene expression profiles (GEP) by itself in this 
sample? 
 
5.2.1 Univariate Analysis:  
Table 8 lists the prognostic variables, their hazard ratios, 95% CI and p-values for the 
comparisons of interest.  3-year and 5-year survival rates of the study sample are listed in 
table 9. 
General Hypothesis: 
H0: No difference between the survival distribution for Group1 and Group 2, (S1 (t) =S2 (t) 
for all t >0) 
 
HA: There is difference in survival distribution between Group1and Group 2, (S1 (t) ≠ S2 (t) 
for some t >0) 
 
Where, Group1: Survival function S1 (t) 
Group 2: Survival function S2 (t) 
If the p-value < alpha (0.05) then H0 is rejected and concluded that group1 and group2 have 
different survival distributions. 
 
If p-value ≥ alpha, H0 is retained and conclude that there no sufficient evidence in the data 
suggesting the opposite is true.  
 
 
 
 
 
 
 
 
 
 
 
31
A) TNM staging:  
 
0.00 
0.25 
0.50 
0.75 
1.00 
Survival in Months
0 20 40 60 80 100 120 140 
Log-Rank p = 0.0513 
Stage 2 (n=29)
Stage 3 (n=29)
 
 
 
Fig 5 Kaplan Meier Survival Curves for TNM Staging of Tumor 
 
H0: No difference between the survival distribution for stage III and stage II CRC, (S1 (t) =S2 
(t) for all t >0). 
 
HA: There is difference in survival distribution between stage III and stage II CRC, (S1 (t) ≠ 
S2 (t) for some t >0). 
 
Patients with stage II CRC had better 3-year and 5-year survival rates compared to patients 
with stage III CRC.  The p-value < alpha (0.05) hence, H0 is rejected and concluded that 
stage III and stage II patients have different survival distributions. 
The hazard ratio for patients with stage III CRC was twice as high than that for 
patients with stage II cancers.  
 
 
 
   3-year rate (%)   5-year rate(%) β HR p-value 
Stage III 68.97  43.97  0.77 2.17 0.0513 
Stage II  75.86  67.65 
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B) Molecular Risk: 
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Fig 6 Kaplan Meier Survival Curves for Molecular Risk  
 
H0: No difference between the survival distribution for high molecular risk patients and low 
molecular risk patients, (S1 (t) =S2 (t) for all t >0). 
 
HA: There is difference in survival distribution between high and low Molecular risk patients, 
(S1 (t) ≠ S2 (t) for some t >0). 
 
Patients of low molecular risk had better 3-year and 5-year survival rates compared to 
patients of the high molecular risk cluster.  The p-value < alpha (0.05) hence, H0 is rejected 
and concluded that low molecular risk and high molecular risk patients have different 
survival distributions.  
According to this univariate analysis, the hazard for death for patients in the high-risk 
gene expression group was double than that for patients in the low-risk gene expression 
group and it is statistically significant. 
 
   3-year rate (%)   5-year rate(%) β  HR p-value 
High Risk 58.06  41.29  0.987 2.68 0.0141 
Low Risk 88.89  71.46 
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C) BMI: 
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Fig. 7 Kaplan Meier Survival Curves for BMI of Patients 
H0: No difference between the survival distribution between patients with body mass index 
>25 and <25, (S1 (t) =S2 (t) for all t >0). 
 
HA: There is difference in survival distribution between between patients with body mass 
index >25 and <25, (S1 (t) ≠ S2 (t) for some t >0). 
 
Patients with BMI > 25 were found to have better survival and lower hazard for death 
than patients with BMI <25 and an inverse relationship were seen between BMI and 
mortality. The hazard for death for patients in the BMI >25 group was 32% lower than that 
for patients in the BMI<25 group 
 
 
 
 
 
   3-year rate (%)   5-year rate(%) β  HR p-value 
BMI >25   84.85  71.46  -1.15 0.317 0.00041 
BMI<25   55  33.39 
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D) Age 
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Fig. 8 Kaplan Meier Survival Curves for Age of Patients 
Patients in the lower 2/3rd age group had better 3-year and 5-year survival rates and 
lower hazard for death than patients who were in the upper 1/3rd age group. The p-value < 
alpha (0.05) hence, H0 is rejected and concluded that older age group patients (upper 1/3 rd 
tertile) have different survival distributions compared to younger patients (lower 2/3rd tertile). 
The hazard for death for patients in the upper 1/3rd age group was double than that for 
patients in the lower 2/3rd age group. 
 
 
 
 
 
   3-year rate (%)   5-year rate(%)  β  HR p-value 
Upper 1/3rd  57.89  34.74  0.74 2.09 0.0555 
Lower 2/3rd  79.49  65.59 
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Gender (HR: 1.58, p=0.2407), race (HR: 0.83, p=0.6932), family history of CRC 
(HR: 0.79, p=0.6568), grade of tumor (HR: 1.42, p=0.4816), preoperative CEA levels (HR: 
2.3, p=0.1461), location of tumor (HR: 0.73, p=0.2092), and total lymph nodes examined 
(HR: 0.84, p=0.6607), were not statistically significantly associated with survival (Table 8).  
Table 9 summarizes the 3-year and 5-year survival estimates of the study population 
following surgery with curative intent based on the prognostic variable.  Decreased survival 
rates were observed for patients in the younger age group (<50 years) and the older age group 
(>70 years) as compared to those in the middle age (50-70 years), with approximately 40-50 
%, 5-year survival rate for patients in the young and old age group following diagnosis of 
CRC.  
Patients who were overweight and obese (BMI>25) at the time of surgery had better 
survival rates compared to patients who were normal or underweight. 
Higher survival rates at year 3 and year 5 were observed for patients in the low 
molecular risk group as compared to those in the high risk group, which were statistically 
significant. Specifically Stage 2 with low molecular risk and stage 3 with low molecular risk. 
Patients with stage II CRC had better survival rates than Stage III patients and as 
cancer progressed, the survival rates showed a trend with decreased survival with time. 
Similar results were observed for lymph node involvement, with better survival rates for 
patients with no nodal involvement as compared to <3 group and > 3 group of nodes positive 
patients and survival rate decreased with time. 
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Table 8 Univariate Analysis 
 
Variable  
Parameter 
Estimate 
Chi-
Square 
Hazard Ratio     
 (95% CI) p-value 
Stage 
(Stage 3 vs Stage 2) 
 
0.776 
 
3.61 
 
2.17 (0.98-4.8) 
 
0.06 
 
Molecular Risk –GEP 
(High risk vs Low risk) 
 
0.987 
 
5.46 
 
2.68 (1.2-6.15) 
 
0.02 
 
Age 
(Upper 1/3rd vs Lower 2/3rd age group) 
 
0.740 
 
3.51 
 
2.09 (0.9-4.5) 
 
0.06 
 
Gender (Female vs Male) 
 
0.456 
 
1.35 
 
1.58 (0.7-3.4) 
 
0.24 
 
Race (Caucasian vs Other) 
 
-0.183 
 
0.16 
 
0.83 (0.3-2.1) 
 
0.64 
 
BMI 
(Overweight and obese vs Normal) 
 
-1.150 
 
7.45 
 
0.317 (0.1-0.7) 
 
0.006 
 
Family History of Colorectal Cancer 
 
-0.276 
 
0.20 
 
0.79 (0.2-2.6) 
 
0.66 
 
Grade/Differentiation 
(Poor vs moderate and well) 
 
0.352 
 
0.49 
 
1.42 (0.5-3.8) 
 
0.48 
 
Regional Lymph Node Involvement  
(N1-N2 vs N0) 
 
0.784 
 
3.40 
 
2.09 (0.9-5.0) 
 
0.06 
 
Location of Primary Tumor 
 
-0.309 
 
1.57 
 
0.73 (0.5-1.2) 
 
0.21 
 
Preoperative CEA Level 
(>5ng/ml vs <5 ng/ml) 
 
0.834 
 
1.99 
 
2.3 (0.7-7.3) 
 
0.16 
 
CEA: Carcinoembriyonic antigen, GEP: gene expression profiles. 
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Table 9: 3-year and 5-year Survival Estimates of the Study Population 
Following Curative Surgery Based on the Prognostic Variable  
 
  Variable 
No. of 
Patients (%) 
3-year survival 
rate (%) 
5-year survival 
rate (%)  
  Age      
  ≤ 50 years 6 10  66.67 50  
  50-70 years 22 38  86.36 75.4  
  ≥ 70 years 30 52  63.33 42.04  
  BMI      
  <18.5 (underweight) 1 2  50 -  
  18.5-24.9 (normal) 18 34  55.56 31.33  
  25.9-29.9 (overweight) 21 40  90 72.73  
  ≥ 30 (obese) 13 25  76.92 68.83  
        
  >25 34 64  84.85 71.08  
  <25 19 36  55 33.39  
  Family History of CRC      
  Yes 8 17 75 -  
  No 38 82 76.32 56  
  Molecular Risk      
  Low 27 47 88.89 71.46  
  High 31 53 58.06 41.29  
  Stage      
  Stage II 29 50 75.86 67.65  
  Stage III 29 50 68.97 43.97  
        
  IIA (T3 N0 M0) 26 45  76.92 67.57  
  IIB (T4 N0 M0) 3 5  66.67 66.67  
  IIIA (T1-2 N1 M0) 2 3  50 50  
  IIIB (T3-4 N1 M0) 14 24  78.57 48.21  
  IIIC (Any T N2 M0) 13 23  61.54 38.46  
  Lymph Node Involvement      
  N0 27 48 77.78 68.87  
  N1 17 30 76.47 51.73  
  N2 12 21 58.33 33.33  
  Grade      
  Well 4 7  75 NA*  
   Moderately 44 77  77.27 55.24  
   Poor 9 16  55.56 44.44  
  Total LN Resected      
  >12 28 48 73.33 57  
  <12 30 52 71.43 50  
NA*: Censored, LN: Lymph Node, CRC: colorectal cancer 
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5.2.2 Multivariate analysis (Stepwise Model Selection): 
Research Question 
3. What does the addition of molecular classification (GEP) together with clinical 
parameters (age, sex, family history, BMI, grade, location of tumor, preoperative 
CEA levels) contribute to the usual clinical predictiveness of outcome (survival) in 
stage II and III colorectal cancer?   
 
General Hypothesis: 
H0: βi =0 (no difference of covariates) 
 
HA:  βi≠0 (covariates influence survival) 
 
where, βi is parameter estimate for multiple variables. 
If p-value >0.05, then H0 is not rejected. 
 
Is based on the Cox proportional hazard model: h (t,x) = h(t0) exp (β x). 
This model allowed the estimation of the effect of each covariate in the presence of the 
others. The hazard ratio for each variable is adjusted for the effects of all of the other 
variables in the multivariate model. 
The aim of the study was to establish whether GEP with clinipathological variables 
provides better prognostic information for patients with stage II and III CRC in addition to 
that afforded by staging alone.  
 In order to address this multivariate analysis using stepwise Cox Regression method 
was used, with threshold of 0.05. Factors that were found to be significant in univariate 
analysis were tested for independent statistical significance in multivariate analysis. Three 
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prognostic variables: molecular risk, BMI and age were found to be independent predictors 
of overall survival (Table 10). Staging of tumor was found to be statistically not significant 
on multivariate model; however, it was retained in the final model in order to determine the 
association of other factors in the presence of clinical staging of tumor.  None of the other 
variables were found to be significant. The likelihood ratio test based on maximum partial 
likelihood estimates was used for eliminating confounding. The results of the multivariate 
analysis for overall patient survival are shown in table 10. 
 
 
 
Table 10: Significant Prognostic Risk Factors for Mortality (Overall Patient Survival) 
Determined by Multivariate Analysis 
 
Variable  
Parameter 
Estimate 
Chi-
Square 
Hazard Ratio     
 (95% CI) p-value 
Stage 
(Stage 3  vs Stage 2) 
 
0.897 
 
2.78 
 
2.45 (0.85-7.04) 
 
0.09 
 
Molecular Risk –GEP 
(High risk vs Low risk) 
 
1.343 
 
5.26 
 
3.83 (1.22-12.06) 
 
0.02 
 
Age 
(Upper 1/3rd vs Lower 2/3rd age group) 
 
1.313 
 
5.21 
 
3.72(1.2-11.49) 
 
0.02 
 
BMI 
(overweight and obese vs  normal) 
 
-1.22 
 
5.78 
 
0.29 (0.11-0.79) 
 
0.016 
 
 
 
 
 
 
 
 
 
 
 
40
E. Multivariate analysis of Molecular Risk and Clinical Stage: 
 
 
 
 
 
 
 
 
 
 
Fig. 9 Kaplan Meier Survival Curves for Clinical Stage and Molecular risk combined. 
 
According to fig 9, that there is difference in overall survival when molecular risk and 
clinical staging were combined in multivariate analysis, and patients of the low molecular 
risk group had better survival outcome than patients with high molecular risk group within 
stage II and stage III clinical staging.  Combining clinical stage with molecular risk 
classification we were able to differentiate patients into different strata. 
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5.2.3 Predictor Model 
Factors, which were prognostically significant (biological or clinical) and met the 
proportional hazard model by the assessment of log-minus log survival plot were included in 
the final model. Stepwise procedure was used and based on the assessment of log likelihood 
statistic final predictor model was selected. 
Hypothesis: 
Ho: Model with more variables (predicted model) is similar to the model with fewer 
variables (basic model). 
 HA: The two models are different. 
 
Basic Model: h (t,x) = h(t0) exp [(β1 (stage) 
Predicted model: h (t,x) = h(t0) exp [(β1 (stage)+ β2 (molecular risk)+ β3 (age)+ β4(body mass 
index)]. 
 
The Cox proportional hazard model: h (t,x) = h(t0) exp (β x), where, h(t0) is base line hazard 
function, h (t,x) is hazard at time t, β is parameter estimate for the variable and x is value for 
each variable denoted by “1” and “0” for presence and absence of the prognostic factor. 
 
Based on the Cox Proportional Hazard Model the hazard ratios observed for stage, molecular 
risk, age and body mass are: 
h (t,x) = h(t0) exp [(β1 (stage)+ β2 (molecular risk)+ β3 (age)+ β 4(body mass index)]. 
h (t, stage III) = exp [(0.897* (1))+ (1.343* (0))+ (1.313*(0))+ (-1.22* (0))]= 2.4522; 
h (t, stage III & high molecular risk) = exp[(0.897* (1))+ (1.343* (1))+ (1.313*(0))+ (-1.22* (0))]= 9.39; 
h (t, stageIII & high mol risk & old age& BMI >25) = exp [(0.897* (1))+ (1.343* (1))+ (1.313*(1))+ (-1.22* 
(1))]= 10.27; 
The hazard ratio for stage alone= 2.452.   And the addition of molecular risk to stage 
increased the hazard to 9.39 and for the final model containing stage, molecular risk, age and 
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BMI was 10.27. So, there is evidence that the advanced tumor stage (stage III), high 
molecular risk, old age and body mass index >25 result in higher the hazard ratio and 
decreased survival.  
Predictor model with clinical stage, molecular risk, age and BMI was compared with 
the model containing clinical stage alone.  The test statistic is equal to the difference between 
the –2LogL value in the model fit statistic for both models. The test statistic = 125.256-
112.659= 12.597, which is greater than Chi-square, 3 degree of freedom and at 95% 
significance = 7.815.   
By observing HR, 95% CI for each factor, and the change in the log likelihood 
statistic, it was ascertained that clinical stage, molecular risk, age and BMI should remain in 
the final model.  Model containing clinical stage in conjunction with molecular risk, BMI, 
and age was a stronger indicator of clinical outcome (p= 0.0056) than model with clinical 
stage alone. 
 
        
Fig.10 Survival Distribution for   Fig.11 Survival Distribution for  
Prediction Model with Stage Prediction Model Containing  
 Stage, Molecular Risk, Age and BMI 
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CHAPTER SIX 
 
DISCUSSION 
 
6.1 Important Findings 
The mean age at diagnosis was 67.17 years (SE= 14.32%). The median age was 
observed to be 70.47 years, and the age range at diagnosis was 26.97 to 92.41 years.  33% of 
patients were in the upper 1/3rd age tertile and 67% were in the lower 2/3rd age tertile.  The 
median survival after surgery for Stage IIA and IIB was 4.6 and 5 years, respectively.  And 
for stage III A, IIIB and IIIC the median survival was 3.7, 4.5 and 4.2 years, respectively.  
The median survival in years following surgery for the low molecular risk group was 4.9 
years and 4.1 years for the high risk group. 
The risk of mortality increased with advance in tumor stage and with age. A 
progressive decrease in 5-year survival rates was evident as cancer progressed from TNM 
stage II A to stage IIIC (table 9).  Low molecular risk patients had better survival outcome 
and 5-year survival rates compared to high molecular risk patient.  
The inverse relationship seen with between BMI >25 and mortality could be due to 
the fact that most patients were overweight before cancer diagnosis and had significant  
weight loss from the time of diagnosis to surgery at which time BMI was recorded and were 
less healthy due to cancer.  Hence, BMI <25 indicates significant weight loss in these 
patients and poor survival rates due to advance in cancer, co-morbid condition and poor 
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immune status.  Patients with BMI >25 at surgery had 32% lower hazard for death than 
patients with BMI<25.  
Although, family history of CRC did not show to be significantly associated with 
poor outcome, information on history of CRC in the family and the size of the patient cohort 
may be insufficient to identify positive family history of CRC as a prognostic factor in this 
study.  A larger patient cohort will be required to definitely determine whether family history 
of CRC at diagnosis improves the accuracy of outcome prediction.    
Significant difference in survival outcome was not observed based on the race, 
because majority of the patients in the study were Caucasians and could not be generalized to 
the population.  Grade, an important factor in survival prediction was not found to be a 
statistically significant prognostic factor, as has been reported in previous studies.  In some 
studies significant difference in survival was seen for preoperative CEA level, lymph node 
resection, regional lymph node involvement, however, in this study no significant difference 
in survival was observed.  
Univariate analysis of the study showed 4 out of 10 variables were statistically 
significantly associated with overall survival (table 8).  Among the clinical variables 
analyzed, gene expression profiling analysis distinguished two groups with significantly 
different survival outcomes (high risk vs low risk, HR: 2.68, p=0.0151, fig6). Borderline 
statistical significance was observed for TNM staging of tumor (stages III vs II, HR: 2.17, 
p=0.0513, fig5).  The strong measure of association indicates that the significance is not due 
to chance alone. 
Being older (>74.27 years) doubled the hazard for death compared to those younger 
(<74.25 years).  Patients with BMI > 25 were found to have better survival and lower hazard 
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for death than patients with BMI <25 and an inverse relationship were seen between BMI 
and mortality.  The hazard for death for patients in the BMI >25 group was 32% lower than 
that for patients in the BMI<25 group (Table 8).  The hazard ratio for patients with lymph 
node involvement was two times higher than patients without nodal involvement. 
The purpose of the study was to investigate the hypothesis that combined assessment 
of clinicopathological factors and gene expression profiles will allow increased accuracy of 
survival prediction for patients with CRC over the use of staging alone.  A significant 
difference in survival was observed between the starta when staging and molecular risk were 
combined (p=0.0301, fig 9).   
In this study it was found that GEP (molecular risk) are powerful predictors of 
survival independent of clinicopathological predictors.  Stage, molecular risk, age and body 
mass index, have been identified as significant prognosticators of survival in this study.  
Combining molecular classification, BMI and age of patients to clinical staging, was a better 
indicator of clinical outcome than clinical staging alone.  
Four prognostic variables: TNM staging, molecular risk, BMI and age were found to 
be independent predictors of overall survival in multivariate analysis.  
 
6.2 Strengths and Weakness of the study: 
Strength: Study had highly specific inclusion and exclusion criteria and limited to only 
primary colorectal cancer of stage II and III patients.  All surgical and pathology reports for 
the study population were individually verified.  To minimize error due to case abstraction, 
majority of the patient’s charts were reviewed by same individual and for the few patients 
whose history was abstracted by other abstractors, the information collected by them was 
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cross validated.  Certain risk factors that could affect the survival were controlled for in this 
study in multivariate analysis by stratifying the variables based on presence or absence of the 
risk factor (postmenopausal hormone use, smoking history, alcohol history).  In the study 
only 10% of the patients were lost to follow-up.  This type of study is useful to obtain 
information on colorectal cancer disease patterns over time and associate such patterns to the 
distribution of time to death among patients diagnosed with colorectal cancer.  A study of 
this nature can be applied to public health practice by identifying factors that are important in 
cancer control and intervention, which can minimize mortality and morbidity by screening 
procedures and early diagnosis and treatment among the general population. 
The study was able to determine the contribution of gene expression profile as a 
predictor along with other parameters in survival prediction in colorectal cancer patients. 
Weakness: The study is a retrospective cohort study from which information on patient’s 
demographics and histopathological characteristic were gathered, which could contribute to 
misclassification.  Due to the small sample size the study lacked power and hence significant 
differences in survival outcomes for certain prognostic variables such as preoperative CEA 
levels, grade and smoking and alcohol history, could not be determined.  Cancer status at the 
end of follow up was ascertained from Moffitt Cancer Registry.  Since 7 patients were lost to 
follow up and this is related to outcome (survival) and this could have caused attrition bias in 
the study.  It is possible that differential misclassification of tumor stage and cause of death 
could have occurred either by recording deaths from other causes as deaths from colorectal 
cancer or vice versa. 
Since most patients were Caucasians the results of this study cannot be generalized to 
the general population, as the study sample does not represent the population in general.  The 
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influence of confounding factors such as smoking and alcohol consumption could not be 
determined in this study, as detailed information could not be obtained from clinical charts.  
Other factors, which could modify the risk of developing CRC such as diet, postmenopausal 
hormone use and physical activity, were not taken into consideration because of inadequate 
information.  Certain factors that could influence survival outcome such as body mass index 
at the baseline (before cancer diagnosis) and the effect of treatment following surgery were 
not taken into consideration during data analysis.   
 
6.3 Consistency with literature: 
As in this study; similar results were seen in other studies that identified stage, 
molecular risk and age as significant prognosticators of survival. Data from literature and 
present study suggest clinical parameters, particularly stage [9, 39, 52], molecular risk 
[11,20, 22], age [1,2, 31] and body mass index [12,16,27] are related to patient survival rate 
and are most reliable prognostic factors. 
Prognostic factors that were found to be significant in other studies but were not 
significant in this study were family history [2, 40], histological grade of tumor [21, 39, 52], 
and preoperative CEA levels [21, 30].  Differences between our study and others are mostly 
due to differences in the number of patients, lack of power, length of follow-up, and grouping 
of continuous variables also because the influence of comorbid conditions on survival which 
could not be analyzed in this study, family history, personal history of cancers, dietary 
history, multivitamin use, physical activity, screening history were not taken into 
consideration because of inadequate information.  
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6.4 Conclusion 
Because of the frequency of the disease, the ability to identify high risk groups, better 
survival of patients with early-stage lesion, and the relative simplicity and accuracy of the 
screening tests, screening for colon cancer should be part of routine care for all adults at the 
age of 50 years, especially those with family history of colorectal cancer.  Periodic evaluation 
following treatment of CRC helps to identify and manage recurrent disease.  
 
6.5 Public Health Importance: 
Colorectal cancer presents a major health problem with an annual estimated incidence rate of 
106,680 new cases of colon cancer and 41,930 rectal cancers in 2006 and together they will 
cause 55,170 deaths in the US. Due to the long natural history of cancer there is time for 
early diagnosis and treatment before it reaches an advanced and incurable stage.  
 Since CRC is highly treatable and detected early, effective preventive approaches 
help reduce the morbidity and mortality associated with due the disease. Removal of 
premalignant lesion (adenoma) at the time of screening (colonoscopy) may be an effective 
form of primary prevention.  
 Certain behavioral factors which modify the risk of developing CRC such as dietary 
habits, physical activity, alcohol and cigarette smoking represent potential means of 
prevention. 
 According to the ACS a guideline listed in Appendix 2, screening helps in early 
detection and reduces the risk of dying from CRC. People who have no identifiable risk 
factors (other than age) should begin regular screening at the age of 50 years. Those who 
have a family history or other risk factors for CRC polyps or cancer should start screening at 
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a younger age and more frequently. 
Following diagnosis and treatment for persons with CRC, periodic evaluation by 
monitoring preoperative CEA levels, aids in earlier identification and management of 
recurrent disease and cancer progression. 
 
6.6 Future directions  
For future studies it will be important to validate the gene expression cluster obtained 
in this study and the predictor model on an independent dataset.  To conduct a prospective 
study of a larger sample size and include people of differences in ethnicity, study the 
prognostic ability of GEP and other factors such as family history, comorbid conditions, 
treatment following surgery, histopathological features (p27, p53, VEGF), vascular, 
perineural and lymphatic invasion and the influence of comorbid conditions on outcome 
prediction.  Analyze the interaction between clinicopathological factors and GEP and other 
outcome measures such as time to relapse and treatment response. To determine if 
differences exists in CRC survival on the basis of screening between those persons who 
underwent regular screening and those who did not undergo regular screening as 
recommended by the American Cancer Society. 
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APPENDIX 1 
 
Colorectal Cancer Prevention 
Colorectal cancer occurs as a result of complex interaction between a person’s inherited 
susceptibility (genetic) and environmental factors. Epidemiological and clinical 
investigations suggest that diet high in fat, calories, protein, alcohol and meat and low in 
calcium and folate are associated with increased with increased incidence of CRC. 
Modifiable factors: 
♦ Diet:  Diet high in fat, meat (both red and white), alcohol and low in calcium and folate 
are associated with increased incidence of CRC. Evidence on whether diet high in fiber 
exerts a protective role in reducing the incidence of CRC is mixed. A high-fiber diet is 
thought to be protective, because it accelerates the rate at which fats pass through the 
bowel and reducing the exposure/contact of the large intestine to carcinogens [26, 40]. 
However, conflicting results are seen in some studies. 
♦ NSAIDS: Some studies reported a reduction in colon cancer incidence with the use of 
aspirin, with a 30% overall reduction in colorectal cancer, including a 50% reduction in 
advanced cases [18]. However, in a follow-up study there was no association between the 
use of aspirin and the incidence of CRC [46]. The use of NSAIDS as a primary 
prevention measure is being considered and will depend on the dose and duration of 
intake. 
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♦ Cigarette smoking: Cigarette smoking is associated with an increased tendency to form 
adenomas and develop into colorectal cancer [2].  Most case control studies of cigarette 
exposure and adenomas have found an elevated risk for smokers.  In the Cancer 
Prevention study II, a large nationwide cohort study, multivariate-adjusted colorectal 
cancer mortality rates were highest among current smokers, intermediate among former 
smokers, and lowest in never smokers, with increased risk after 20 or more years of 
smoking history among both men and women.  Based on this study data, it was estimated 
that 12% of colorectal cancer deaths in the US population in 1997 were attributable to 
smoking (Chao, A et al, 2000).  A positive relationship between alcohol intake and large 
bowel cancers was seen in some studies [10]. 
♦ Vitamins: An inverse association was found between the risk of CRC and intake of 
vitamins E; the RR for the highest compared to the lowest quartile was 0.3 (95% CI, 
0.19-0.54) [6]. A similar association was seen for Vitamin D and folic acid intake and 
risk of CRC [17]. 
♦ Calcium: Several studies have observed an inverse relationship between calcium intake 
and cancer risk. Orally ingested calcium binds with bile acids and fatty acids released 
into the intestine following a high fat diet, to form insoluble compounds which are not 
harmful to the colonic mucosa and thereby reduces the exposure to the toxic effects of 
bile acids [43]. 
♦ Post menopausal female hormones: Epidemiologic Studies have suggested a decreased 
risk of colon cancer among users of postmenopausal female hormone supplements [10] 
 
 
 
56
♦ Physical activity: An inverse relationship is seen between level of physical activity and 
colon cancer incidence. A sedentary lifestyle has been associated with an increased risk 
of colorectal cancer in some studies [13, 44] but not all [27].  
♦ Colonscopy: Colonscopy with the removal of adenomatous polyps helps in reducing the 
risk of CRC. 
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APPENDIX 2 
ACS Screening Guidelines 
Beginning at age 50, men and women should have 1 of the 5 screening option below: 
1. A fecal occult blood test (FOBT) or fecal immunochemical test (FIT) every  year 
2. Flexible sigmoidoscopy every 5 years 
3. FOBT/FIT every year plus sigmoidoscopy every 5 years 
4. Double contrast barium enema every 5 years or 
5. Colonoscopy every 10 years. 
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APPENDIX 3 
 
 
CLINICAL CHART REVIEW DATA ENTRY FORM 
 
Note:   Dates are entered in MM/DD/YYYY format. 
 If month or day is unknown, specify value as 01. 
 If entire date is unknown, specify value as 01/01/1111 
 
2. Moffitt medical record number   
3-4. Tissue for study: 
Note:  This tissue should be the 
earliest colorectal primary;  if 
colorectal primary tissue not 
available, then earliest available 
other site   
1 First colorectal primary 
2 Second colorectal primary 
3 Local recurrence 
4 Appendiceal adenocarcinoma 
5 Hepatic metastasis 
6 Pulmonary metastasis 
7 Other metastasis: 
       Site  _________________________  (4) 
5. Date of collection   /            / 
6. Surgical Accession Number  S -  ______________________ 
7. Gender   
 
0 Male 
1 Female 
8. Race/ethnicity 1 Caucasian 
2 African American 
3 Hispanic 
4 Asian 
5 Other/unknown 
9. 
 
Date of birth (MM/DD/YYYY) 
 
/            / 
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10-18. Clinical presentation with 
index primary colorectal 
cancer: 
 None recorded 
 Asymptomatic 
 Melena 
 Hematochezia 
 Change in bowel habits 
 Abdominal pain 
 Weight loss 
 Clinically “Obstructed” 
 
 Hct at presentation 
 
 
0 No 1 Yes (10) 
0 No 1 Yes (11) 
0 No 1 Yes (12) 
0 No 1 Yes (13) 
0 No 1 Yes (14) 
0 No 1 Yes (15) 
0 No 1 Yes (16) 
0 No 1 Yes (17) 
 
 ____________   (18) 
19. Weight loss in lbs prior to  
presentation with index primary 
colorectal cancer 
 (use 999 if unknown) 
 
20. Weight in lbs at presentation with 
index primary colorectal cancer 
 (use 999 if unknown) 
 
21. 
 
Height in inches 
 (use 999 if unknown) 
 
22-40. Charlson Index comorbidities: 
 Myocardial infarct 
 Congestive heart disease 
 Peripheral vascular disease 
 Cerebrovascular disease 
 Dementia 
 Chronic pulmonary disease 
 Connective tissue disease 
 Peptic ulcer disease 
 Mild liver disease 
 Diabetes 
 Hemiplegia 
 Moderate/severe renal disease 
 Diabetes w/ end organ disease 
 Non-metastatic cancer, 
  other than colon cancer 
 Metastatic cancer, 
  other than colon cancer 
 
0 No/unknown  1 Yes (22) 
0 No/unknown  1 Yes (23) 
0 No/unknown  1 Yes (24) 
0 No/unknown  1 Yes (25) 
0 No/unknown  1 Yes (26) 
0 No/unknown  1 Yes (27) 
0 No/unknown  1 Yes (28) 
0 No/unknown  1 Yes (29) 
0 No/unknown  1 Yes (30) 
0 No/unknown  1 Yes (31) 
0 No/unknown  1 Yes (32) 
0 No/unknown  1 Yes (33) 
0 No/unknown  1 Yes (34) 
0 No/unknown  1 Yes (35) 
 
0 No/unknown  1 Yes (36) 
0 No/unknown  1 Yes (37) 
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 Leukemia 
 Lymphoma 
 Moderate/severe liver disease 
 AIDS 
 
 
 
 
 
0 No/unknown  1 Yes (38) 
0 No/unknown  1 Yes (39) 
0 No/unknown  1 Yes (40) 
41-44. Smoking history 
Packs per day 
Years 
Pack-years 
If any quantity unknown, 
specify “999.”  Give only 
numbers from chart. 
0 No 1 Yes 2 Unknown   
(41) 
__________  (42) 
__________  (43) 
__________  (44) 
 
45. History of alcohol use 0 No 1 Yes 2 Unknown 
46. History of  
hormone replacement therapy 0 No 1 Yes 2 Unknown 
47 - 55. Personal history of cancer  
other than the index primary 
colorectal cancer  
 
 
 
 
 
 
 
 
 
 
 
 Cancer #1 Cancer #2 Cancer #3 
  ________  (47) ______  (48) ______  (49) 
CODING KEY - additional primary cancers  
0 Primary of 5 Urothelium 
 unknown origin  (renal pelvis, 
    ureter, 
bladder) 
1  2nd Colorectal 6 Endometrium 
2 Stomach 7 Ovary 
3 Small Intestine 8 Brain 
4 Ampulla 9 Other 
  99 None 
 
Cancer #1 ___________________________  
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If cancer is “9  Other,” specify 
primary: 
 
 
 
 
 
Did the additional primary 
cancer  coexist with the index 
primary colorectal cancer? 
 
 Cancer #1 
 
 Cancer #2 
 
 Cancer #3 
 
 
(50) 
Cancer #2 ___________________________  
(51) 
Cancer #3 ___________________________  
(52) 
 
 
 
 
 
 
 
0 No 1 Yes 2 Unknown  
(53) 
 
0 No 1 Yes 2 Unknown  
(54) 
 
0 No 1 Yes 2 Unknown  
(55) 
56-92. Family history recorded in chart? 
Family history of cancer: 
 
 Family member     # 1 
  # 2 
  # 3 
  # 4 
  # 5 
  # 6 
  # 7 
  # 8 
  # 9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 No 1 Yes   (56) 
 
Relation 2nd Primary Primary 
to Patient Degree? Cancer #1 Cancer 
#2 
_______ (57)  _____ (58) _____ (59) _____ 
(60) 
_______ (61)  _____ (62) _____ (63) _____ 
(64) 
_______ (65)  _____ (66) _____ (67) _____ 
(68) 
_______ (69)  _____ (70) _____ (71) _____ 
(72) 
_______ (73)  _____ (74) _____ (75) _____ 
(76) 
_______ (77)  _____ (78) _____ (79) _____ 
(80) 
_______ (81)  _____ (82) _____ (83) _____ 
(84) 
_______ (85)  _____ (86) _____ (87) _____ 
(88) 
_______ (89)  _____ (90) _____ (91) _____ 
(92) 
CODING KEY – Relation to Patient 
0 Unknown 7 Grandmother 
1 Mother 8 Grandfather 
2 Father 9 Aunt 
3 Sister 10 Uncle 
4 Brother  99 No cancer 
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5 Daughter 
6 Son 
CODING KEY - 2nd Degree? 
0 1st degree or unknown 
1 maternal 2nd degree relative 
2 paternal 2nd degree relative 
Note:  2nd degree relatives are 
grandparents, aunts and uncles 
 
CODING KEY - Primary Cancer  
0 Primary of 5 Urothelium 
 unknown origin  (renal pelvis, 
    ureter, 
bladder) 
1 Colorectum 6 Endometrium 
2 Stomach 7 Ovary 
3 Small Intestine 8 Brain 
4 Ampulla  9 Other 
93. Location of index primary 
colorectal adenocarcinoma in 
patient 
1 Cecum  & Ileocecal Valve 
2 Appendix   
3 Ascending colon  (Right colon) 
4 Hepatic flexure of colon 
5 Transverse colon  
6 Splenic flexure of colon   
7 Descending colon  (Left colon) 
8 Sigmoid colon   
9 Colon, NOS 
10 Rectosigmoid junction (Rectosigmoid 
colon) 
11 Rectum  
94-97. TNM tumor stage at time of 
surgery for index primary 
colorectal cancer  
 
 
 
 
Primary Tumor (T)      (94) 
 
0 T0 – No evidence of primary tumor 
 
1 T1 – Tumor invades submucosa 
 
2 T2 – Tumor invades muscularis propria 
 
3 T3 – Tumor invades through the 
muscularis propria into the subserosa, or 
into non-peritonealized pericolic or 
perirectal tissues 
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TNM staging  (continued) 
4 T4 – Tumor directly invades other organs 
or structures, and/or perforates visceral 
peritoneum 
 
 Note 1:  Direct invasion in T4 includes 
invasion of other segments of the 
colorectum by way of the serosa;  for 
example, invasion of the sigmoid colon 
by a carcinoma of the cecum 
 Note 2:  Tumor that is adherent to other 
organs or structures, macroscopically, is 
classified as T4 
 
5 TX – Primary tumor cannot be assessed 
 
6 Tis – Carcinoma in situ;  intraepithelial 
or invasion of lamina propria 
 
 Note:  Tis includes cancer cells confined 
within the glandular basement membrane 
(intraepithelial) or lamina propria 
(intramucosal) with no extension through 
the muscularis mucosa into the 
submucosa 
 
 
Regional Lymph Nodes (N)     (95) 
 
0 N0 – No regional lymph node metastasis 
 
1 N1 – Metastasis in 1 to 3 regional lymph 
nodes 
 
2 N2 – Metastasis in 4 or more regional 
lymph nodes 
 
3 NX – Regional lymph nodes cannot be 
assessed 
 
 
Distant Metastasis (M)       (96) 
 
0 M0 – No distant metastasis 
 
1 M1 – Distant metastasis 
 
2 MX – Distant metastasis cannot be 
assessed 
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Radial Margins and Residual Tumor (R)        (97) 
 
0 R0 – Complete resection, margins 
histologically negative, no residual tumor 
left after resection 
 
1 R1 – Incomplete resection, margins 
histologically involved, microscopic 
tumor remains after resection of gross 
disease 
 
2 R2 – Incomplete resection, margins 
involved or gross disease remains after 
resection 
 
3 Resection margins cannot be assessed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
98. Tumor stage  at time of surgery 
for index primary colorectal 
cancer  (use TNM classification 
to determine stage) 
0 Stage 0  Tis N0 M0 
1   Stage I  T1 N0 M0 
  T2 N0 M0 
2 Stage IIA  T3 N0 M0 
3 Stage IIB T4 N0 M0 
 
4 Stage IIIA  T1-T2 N1 M0 
 
5 Stage IIIB  T3-T4 N1 M0 
 
6 Stage IIIC  Any T N2 M0 
 
7 Stage IV  Any T Any N M1   
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8 Tumor stage cannot be assessed 
99. Histologic grading of index 
primary adenocarcinoma 
1 G1 – Well differentiated 
2 G2 – Moderately well differentiated 
3 G3 – Poorly differentiated 
4 G4 – Undifferentiated 
9 GX – Grade not determined or unspecified 
100. Histology – 
 Mucinous component? 
0 No mucinous component noted 
1 Yes 
101. Histology –  
 Signet ring cells? 
0 No signet ring cells noted 
1 Yes 
102. Histology – 
 Perineural invasion? 
0 No perineural invasion noted 
1 Yes 
103. Histology – 
 Lymphatic invasion? 
0 No lymphatic invasion noted 
1 L –  Microscopic lymphatic invasion 
104. Vascular invasion? 0 No vascular invasion noted 
1 V1 – Microscopic vascular invasion 
2 V2 – Macroscopic vascular invasion 
105-
108. 
Metastases present at time of 
surgery for index primary 
colorectal cancer: 
Liver 
Lung 
Metastasis other than liver or 
lung 
 
 
 
 
0 No 1 Yes   (105) 
0 No 1 Yes   (106) 
0 No 1 Yes   (107) 
Site(s):  __________________________  (108) 
109. Date of surgery for index 
primary colorectal cancer 
(MM/DD/YYYY) 
 
If month or day is unknown, 
specify value as 01.  If entire 
date is unknown, specify value 
 
/            / 
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as 01/01/1111. 
 
110. Type of surgery for index 
primary colorectal cancer 
0 Not resected 
1 Subtotal colectomy 
2 Right hemicolectomy 
3 Transverse colectomy 
4 Left hemicolectomy 
5 Sigmoid resection 
6 Low anterior resection (rectal cancer) 
7 Abdominoperineal resection (rectal cancer) 
111. Were resection margins clear 
on index primary colorectal 
cancer? 
0 No 
1 Yes 
2 Primary not resected 
3 Unknown 
112-
113. 
Size of index primary 
colorectal cancer from 
pathology report 
 
 Length along axis of colon  _________  cm   
(112) 
 Maximum diameter  __________  cm   (113)  
114-
115. 
Number of nodes taken at 
resection of index primary 
colorectal cancer 
Number of these nodes that 
were positive for cancer 
____________  (114) 
 
____________  (115) 
116-
123. 
Treatment for hepatic 
metastasis present at time of 
surgery for index primary 
colorectal cancer: 
 Surgical treatment 
 Wedge resection 
 Segmentectomy 
 Lobectomy 
 Radio frequency ablation 
 Infusion pump 
Timing of this treatment for 
hepatic metastasis present at 
surgery for index primary 
colorectal cancer: 
  
 
0 No 1 Yes   (116) 
0 No 1 Yes   (117) 
0 No 1 Yes   (118) 
0 No 1 Yes   (119) 
0 No 1 Yes   (120) 
0 No 1 Yes   (121) 
 
(122)   
0 None of the above treatments done for 
hepatic metastasis at time of surgery or later 
1 Treatment done at time of surgery 
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2 Treatment delayed until a later time 
  Date   ______ / ______ / ______  (123) 
124-
126. 
Treatment for pulmonary 
metastases at time of surgery 
for index primary colorectal 
cancer: 
 Surgical treatment 
 Wedge resection 
 Lobectomy 
  
 
0 No 1 Yes   (124) 
0 No 1 Yes   (125) 
0 No 1 Yes   (126) 
127. Preoperative treatment 
for index primary 
colorectal cancer 
 
0 None 
1 Chemotherapy 
2 Radiation therapy 
3 Both 
128. Intra-operative radiation therapy at 
time of treating index primary? 
0 No 1 Yes 
129. Postoperative treatment 
for index primary 
colorectal cancer 
 
0 None 
1 Chemotherapy 
2 Radiation therapy 
3 Both 
130. Recurrence of index primary 
colorectal cancer (radiographic) 0 No 1 Yes 2 Unknown 
131-
135. 
Sites of recurrent colorectal 
cancer: 
Local 
Liver 
Lung 
Sites other than liver or lung 
 
 
 
 
0 No 1 Yes   (131) 
0 No 1 Yes   (132) 
0 No 1 Yes   (133) 
0 No 1 Yes   (134) 
Site(s):  ____________________________  
(135) 
136. Date recurrence discovered   /            / 
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(MM/DD/YYYY) 
If month or day is unknown, 
specify value as 01.  If entire 
date is unknown, specify value 
as 01/01/1111. 
137-
139. 
Treatment of recurrent disease: 
Surgical resection 
Radio frequency ablation 
(RFA) 
Chemotherapy 
 
 
 
0 No 1 Yes 2 Unknown  
(137) 
 
0 No 1 Yes 2 Unknown  
(138) 
 
0 No 1 Yes 2 Unknown  
(139) 
140. Date of treatment of recurrence 
by resection or RFA. 
 
If month or day is unknown, 
specify value as 01.  If entire 
date is unknown, specify value 
as 01/01/1111. 
  /            / 
141. Date of last recorded contact 
with patient in chart 
If month or day is unknown, 
specify value as 01.  If entire 
date is unknown, specify value 
as 01/01/1111. 
  /            / 
142-
209. 
CEA: 
 
 
 
 
 
Date drawn  Level 
______ /______ / ______  (142) ________  
(143) 
______ /______ / ______  (144) ________  
(145) 
______ /______ / ______  (146) ________  
(147) 
______ /______ / ______  (148) ________  
(149) 
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CEA   (continued)  
 
 
 
 
 
 
 
______ /______ / ______  (150) ________  
(151) 
______ /______ / ______  (152) ________  
(153) 
______ /______ / ______  (154) ________  
(155) 
______ /______ / ______  (156) ________  
(157) 
______ /______ / ______  (158) ________  
(159) 
______ /______ / ______  (160) ________  
(161) 
______ /______ / ______  (162) ________  
(163) 
______ /______ / ______  (164) ________  
(165) 
______ /______ / ______  (166) ________  
(167) 
______ /______ / ______  (168) ________  
(169) 
Date drawn  Level 
______ /______ / ______  (170) ________  
(171) 
______ /______ / ______  (172) ________  
(173) 
______ /______ / ______  (174) ________  
(175) 
______ /______ / ______  (176) ________  
(177) 
______ /______ / ______  (178) ________  
(179) 
______ /______ / ______  (180) ________  
(181) 
______ /______ / ______  (182) ________  
(183) 
______ /______ / ______  (184) ________  
(185) 
______ /______ / ______  (186) ________  
(187) 
______ /______ / ______  (188) ________  
(189) 
______ /______ / ______  (190) ________  
(191) 
______ /______ / ______  (192) ________  
(193) 
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______ /______ / ______  (194) ________  
(195) 
______ /______ / ______  (196) ________  
(197) 
______ /______ / ______  (198) ________  
(199) 
______ /______ / ______  (200) ________  
(201) 
______ /______ / ______  (202) ________  
(203) 
______ /______ / ______  (204) ________  
(205) 
______ /______ / ______  (206) ________  
(207) 
______ /______ / ______  (208) ________  
(209) 
 
210. Second tissue for study: 
Note:  This tissue cannot be a first colorectal 
primary;  if second tissue available, then it 
should be the next earliest available site 
1 none 
2 Second colorectal primary 
3 Local recurrence 
4 Appendiceal adenocarcinoma 
5 Hepatic metastasis 
6 Pulmonary metastasis 
7 Other metastasis: 
      Site  _________________________  
(211) 
212. Date of collection, 
      second tissue   /            / 
213. Surgical Accession Number, 
      second tissue  S -  ______________________ 
214. Third tissue for study: 
Note:  This tissue cannot be a first 
colorectal primary;  if second 
tissue available, then it should be 
the next earliest available site 
1 none 
2 Second colorectal primary 
3 Local recurrence 
4 Appendiceal adenocarcinoma 
5 Hepatic metastasis 
6 Pulmonary metastasis 
7 Other metastasis: 
      Site  _________________________  
(215) 
216. Date of collection, 
     third tissue   /            / 
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217. Surgical Accession Number, 
     third tissue  S -  ______________________ 
 
